Welcome to our dedicated page for SpyGlass Pharma news (Ticker: SGP), a resource for investors and traders seeking the latest updates and insights on SpyGlass Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SpyGlass Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SpyGlass Pharma's position in the market.
SpyGlass Pharma (SGP) will participate in three investor conferences in September 2026, featuring meetings, a fireside chat and a corporate presentation.
Events include the Wells Fargo 21st Annual Healthcare Conference on September 9, Citi’s 2026 Biopharma Back to School Conference on September 10, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. Webcasts for the Citi fireside chat and H.C. Wainwright presentation will be available via the company’s Investor Relations website.
SpyGlass Pharma (Nasdaq: SGP) reported second quarter 2026 results and clinical updates. The company held $234.2 million in cash, cash equivalents and short-term investments as of June 30, 2026, which it expects will fund planned operations through 2028.
Enrollment in the parallel registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) remains on track, with completion expected in 2027, and a first-in-human trial of the Bimatoprost-Drug Ring System (BIM-DRS) is expected to start in the second half of 2026. In May 2026, the AMA approved a dedicated add-on Category III CPT code (+1090T) for use with established cataract surgery codes, creating a specific reimbursement pathway for the BIM-IOL System. Second quarter 2026 research and development expenses were $10.9 million and general and administrative expenses were $11.0 million, leading to a net loss of $19.9 million, or $(0.59) per share.
SpyGlass Pharma (Nasdaq: SGP) appointed Shannon Treviño as general counsel. She is a healthcare-focused legal executive with corporate, M&A, and securities experience, including guiding Inari Medical through its $4.9 billion acquisition by Stryker. The hire comes as SpyGlass advances its BIM-IOL System through Phase 3 trials and prepares for potential commercialization.
SpyGlass Pharma (Nasdaq: SGP) appointed Mike Pinder as vice president, marketing. He brings over 20 years of ophthalmology commercial launch experience, including roles at Astellas, Novartis, and Johnson & Johnson.
Pinder will build and lead marketing as SpyGlass advances its BIM-IOL System through Phase 3 trials toward potential FDA-approved commercialization.
SpyGlass Pharma (Nasdaq: SGP) announced that its executive management will participate in three upcoming investor events focused on healthcare and ophthalmology.
These include the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 4, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. All sessions feature fireside chats or a corporate presentation, with live webcasts and replays available on the company’s investor relations website.
SpyGlass Pharma (Nasdaq: SGP) announced AMA approval of a new add-on Category III CPT code +X659T for attachment and insertion of an intraocular lens prosthesis-mounted drug-eluting implant, based on its Bimatoprost Drug Pad-IOL (BIM-IOL) System, used with existing cataract surgery codes.
The BIM-IOL System targets elevated intraocular pressure in open-angle glaucoma or ocular hypertension patients with cataracts and is in two Phase 3 trials, with enrollment expected to complete in 2027.
SpyGlass Pharma (Nasdaq: SGP) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and short-term investments were $251.0 million as of March 31, 2026, expected to fund operations through 2028.
Phase 1/2 BIM-IOL data showed 34% mean IOP reduction at 78-mcg, 98% of patients free from topical IOP-lowering drops and 100% achieving BCDVA 20/32 or better, with a safety profile comparable to routine cataract surgery. Parallel Phase 3 BIM-IOL trials SGP-005 and SGP-006 have begun surgeries, with enrollment completion expected in 2027. The BIM-DRS first-in-human trial is planned for the second half of 2026. Net loss was $13.8 million, or ($0.69) per share, versus $8.8 million, or ($3.96) per share, a year earlier.
SpyGlass Pharma (Nasdaq: SGP) reported positive clinical progress and strengthened finances after its February 2026 IPO that raised $172.5 million. The Phase 1/2 BIM-IOL System topline showed sustained IOP control and elimination of topical IOP-lowering drops in ~97% of participants at 12 months.
Phase 3 enrollment is underway, cash resources are expected to fund operations through 2028, and a BIM-DRS first-in-human trial is planned for H2 2026.
SpyGlass Pharma (NASDAQ: SGP) announced positive topline 12-month Phase 1/2 results for the BIM-IOL System on March 9, 2026. In 104 randomized patients (2:1:1), the 78-mcg and 39-mcg groups showed 34% and 42% mean IOP reductions at 8 a.m., versus 35% for control.
At 12 months 98% (78-mcg) and 96% (39-mcg) of evaluable patients were free of topical IOP medications; 100% achieved 20/32 or better BCDVA with mean BCDVA of 86 letters (≈20/20). AE rates were similar across arms; no serious ocular AEs. Two pivotal Phase 3 trials began randomizing in January 2026.
SpyGlass Pharma (Nasdaq: SGP) said its executive management team will host one-on-one meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026.
The meetings are management-led 1x1 investor sessions during the conference, offering direct Q&A opportunities.